Here, we reported a novel engineered MSC‐EVs (nor@MSC‐EVs), which are loaded with Arg1 inhibitor (nor‐NOHA) through electroporation for the synergistic therapy of psoriasis via modulating both local and systemic metabolic and immunological disorders (Scheme1). Here, ARG1 is linked to psoriasis.